Literature DB >> 11595295

Lipopeptide presentation pathway in dendritic cells.

A Hosmalin1, M Andrieu, E Loing, J F Desoutter, D Hanau, H Gras-Masse, A Dautry-Varsat, J G Guillet.   

Abstract

Lipopeptides are currently being evaluated as candidate vaccines in human volunteers. They elicit cytotoxic responses from CD8(+) T lymphocytes, whereas peptides without a lipidic moiety usually do not. The exact processing and presentation pathways leading to association with MHC class I molecules has not yet been defined. This is of particular interest in dendritic cells, which are required for primary T cell stimulation. We have tracked lipopeptides derived from an HLA-A2.1-restricted HIV-1 Reverse Transcriptase epitope, by N-terminal addition of an N-epsilon-palmitoyl-lysine. Entry of the lipopeptides into human monocyte-derived dendritic cells (MDC) was mediated by endocytosis, as assessed by colocalization using analogs labelled with rhodamine, and by confocal microscopy. This internalization in DC induced functional stimulation of CD8(+) T lymphocytes specific for the epitopes, quantified by Interferon-gamma ELISPOT assays. The peptide alone was not visualized inside the DC and was only presented through direct surface association to HLA-A*0201. Therefore, lipopeptides provide a model system to define precisely the cross-presentation pathways that lead exogenous proteins to associate with class I MHC molecules within dendritic cells. Using this approach, cross-presentation pathways can be better defined and vaccine lipopeptides can be further optimized for MHC class I association in human dendritic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595295     DOI: 10.1016/s0165-2478(01)00271-1

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  Mitogenicity of the recombinant mycobacterial 27-kilodalton lipoprotein is not connected to its antiprotective effect.

Authors:  Avi-Hai Hovav; Liuba Davidovitch; Gabriel Nussbaum; Jacob Mullerad; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.

Authors:  Xiuli Zhang; Annie Issagholian; Eric A Berg; Jordan B Fishman; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 3.  TLR-based immune adjuvants.

Authors:  Folkert Steinhagen; Takeshi Kinjo; Christian Bode; Dennis M Klinman
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

4.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

Review 5.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

Review 6.  Cancer immunotherapy and nanomedicine.

Authors:  Wei-Yun Sheng; Leaf Huang
Journal:  Pharm Res       Date:  2010-09-04       Impact factor: 4.580

7.  Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.

Authors:  Odile Launay; Christine Durier; Corinne Desaint; Benjamin Silbermann; Angela Jackson; Gilles Pialoux; Bénédicte Bonnet; Isabelle Poizot-Martin; Gustavo Gonzalez-Canali; Lise Cuzin; Suzanne Figuereido; Mathieu Surenaud; Nadine Ben Hamouda; Hanne Gahery; Jeannine Choppin; Dominique Salmon; Corinne Guérin; Isabelle Bourgault Villada; Jean-Gérard Guillet
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.